A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin
 LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.
Inclusion Criteria:

 -  Diagnosis of acromegaly

 -  IGF-I levels >=1.3xULN (upper limit of normal) at screening

 -  No history of radiotherapy or prior treatment with other drugs for acromegaly

 -  Minimum of two months must have elapsed post surgery prior to screening

 Exclusion Criteria:

 -  Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or
 IGF-I concentrations

 -  AST/ALT >= 3xULN (upper limit of normal)

 -  Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI

 -  Visual field defects (except post surgical stable residual defects)

 -  Unable to self administer drug